AbbVieABBV
A drugmaker whose medicines include Skyrizi and Rinvoq for immune diseases, and Botox; its former top seller, Humira, now competes with cheaper copies.
Preview
Hindsight Analysis is coming
We’re building deeper investigations of the companies shaping the news: what their figures reveal, the risks behind headline results, and how management’s promises compare with what the company delivered. Every assessment will be dated, so you can see later how it held up.
Join the waitlist to hear when it opens, and to tell us you’d like AbbVie covered.
Charts and live prices are delayed, from TradingView. Market values use each company’s last trade on IEX at the previous close, times the shares in issue from its filings; company figures come from SEC filings. This is information, not investment advice. Where our market data comes from
Company logos are trademarks of their owners, shown only to identify them; the files are from Wikimedia Commons.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.